Robert L. Fine, MD

Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.

In a phase II trial, CAPTEM elicited a response rate of 45% and a stable disease rate of 52%.

Carcinoids, which represent the majority of all neuroendocrine tumors and typically have a response rate of 0-4%, showed a 45% response rate in this study.

CAPTEM was well tolerated: Just 10-15% of patients experienced grade 3 toxicities.

Videos

Robert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.

The Utility of CAPTEM in Chemo-Resistant Neuroendocrine Tumors

Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.

a hedgehog pathway inhibitor for the treatment of advanced pancreatic cancer > >

Articles

Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.

Robert L. Fine, MD | Authors

Articles

The Utility of CAPTEM in Chemo-Resistant Neuroendocrine Tumors

Reducing the Risk of Relapse in Patients With Pancreatic Cancer